Produção Nacional
Alendronate sodium-polymeric nanoparticles display low toxicity in gastric mucosal of rats and Ofcol II cells
2021; Elsevier BV; Volume: 24; Linguagem: Inglês
10.1016/j.impact.2021.100355
ISSN2452-0748
AutoresBruno Iles, Isabela Ribeiro de Sá Guimarães Nolêto, Flaviane França Dourado, Fábio de Oliveira Silva Ribeiro, Alyne Rodrigues de Araújo, Taiane Maria de Oliveira, Jéssica Maria Teles Souza, Ayslan B. Barros, Gabrielle Costa Sousa, Antônia Carla de Jesus Oliveira, Conceição da Silva Martins, Mariana de Oliveira Viana Veras, Renata Ferreira de Carvalho Leitão, José Roberto de Souza de Almeida Leite, Durcilene Alves da Silva, Jand Venes Rolim Medeiros,
Tópico(s)Radiopharmaceutical Chemistry and Applications
ResumoThe use of bisphosphonates constitutes the gold-standard therapy for the control and treatment of bone diseases. However, its long-term use may lead to gastric problems, which limits the treatment. Thus, this study aimed to formulate a nanostructured system with biodegradable polymers for the controlled release of alendronate sodium. The nanoparticles were characterized, and its gastric toxicity was investigated in rats. The synthesis process proved to be effective for encapsulating alendronate sodium, exhibiting nanoparticles with an average size of 51.02 nm and 98.5% of alendronate sodium incorporation. The release tests demonstrated a controlled release of the drug in 420 min, while the morphological analyzes showed spherical shapes and no apparent roughness. The biological tests demonstrated that the alendronate sodium nanoformulation reversed the gastric lesions, maintaining the normal levels of malondialdehyde and myeloperoxidase. Also, the encapsulated alendronate sodium showed no toxicity in murine osteoblastic cells, even at high concentrations.
Referência(s)